What changed: Biochemical recurrence of prostate cancer
Every dated change on the records linked to Biochemical recurrence of prostate cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Trial result4Milestone5This record1
September 2026 · 1
2023 · 3
- 2023Trial resultEMBARKEMBARK reported
MFS HR 0.
- 2023Trial resultSPOTLIGHTSPOTLIGHT reported
Overall detection rate 83% by majority read; verified detection rate against a composite standard of truth was 51-54% across readers, meeting the pre-specified threshold, though combined region-level positive predictive value (46-60%) did not (Jani et al.
- 2023MilestoneEMBARKEMBARK: enzalutamide delays metastasis in high-risk biochemical recurrence
A milestone in how this cancer is treated.